AstraZeneca PLC (AZN)
NASDAQ: AZN · Real-Time Price · USD
73.76
+0.23 (0.31%)
At close: Sep 26, 2025, 4:00 PM EDT
73.75
-0.01 (-0.01%)
After-hours: Sep 26, 2025, 7:45 PM EDT
AstraZeneca Revenue
AstraZeneca had revenue of $14.46B in the quarter ending June 30, 2025, with 11.74% growth. This brings the company's revenue in the last twelve months to $56.50B, up 15.00% year-over-year. In the year 2024, AstraZeneca had annual revenue of $54.07B with 18.03% growth.
Revenue (ttm)
$56.50B
Revenue Growth
+15.00%
P/S Ratio
4.05
Revenue / Employee
$608,192
Employees
92,900
Market Cap
228.75B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 54.07B | 8.26B | 18.03% |
| Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
| Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
| Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
| Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
| Thermo Fisher Scientific | 43.21B |
AZN News
- 1 day ago - A New Prescription For Pain: Understanding Trump's 100% Pharma Tariff - Seeking Alpha
- 1 day ago - AstraZeneca to Offer Discounted Drugs As Trump Pressures Pharma Industry to Cut Prices - WSJ
- 1 day ago - AstraZeneca launches direct-to-consumer platform to expand access to medications for US patients, including those living with chronic conditions - Business Wire
- 1 day ago - AstraZeneca to cut some direct-to-patient US drug prices after Trump demand - Reuters
- 2 days ago - AstraZeneca: Oncology Breakthroughs And Farxiga Surge Excite Investors - Seeking Alpha
- 3 days ago - ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab granted Priority Review in the US as 1st-line treatment for patients with HER2-positive metastatic breast cancer - Business Wire
- 5 days ago - European Advisory Panel Recommends Two AstraZeneca Drugs For Approval - Benzinga
- 5 days ago - SOPHiA GENETICS Expands Collaboration with AstraZeneca to Enhance Detection of Breast and Prostate Cancer - PRNewsWire